文献速递肝病消化内镜

肝-心炎症轴与CB2受体信号在实验性肝心肌病中的相互作用

Interplay of Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy.
PubMed 文献 · Hepatology · 2020-01-24

该研究在胆管结扎(BDL)诱导肝纤维化小鼠模型中,通过超声心动图和心内压力-容积关系监测详细血流动力学及心肌结构改变,并用选择性CB2受体激动剂干预。BDL小鼠出现肝脏炎症、氧化应激、微血管功能障碍和纤维化,伴舒张、收缩及大血管功能受损和心脏炎症、氧化应激;CB2受体激活可改善肝脏炎症、微循环和纤维化,并降低血清TNF-α、改善心脏功能障碍、心肌炎症和氧化应激。

要点

  • BDL小鼠可作为肝/肝硬化心肌病模型,表现为全身低血压及大血管和微血管功能受损,伴收缩和舒张功能障碍
  • 肝-心炎症轴在肝心肌病发生中具有关键病理生理作用
  • 控制肝脏和/或心肌炎症(如选择性CB2受体激动剂)可能延缓或预防严重肝病中心肌病的发生

核心结论

  • BDL诱导的小鼠心肌病可作为肝/肝硬化心肌病模型,其特征为全身低血压及大血管和微血管功能受损,伴收缩和舒张功能障碍。
  • 肝-心炎症轴在肝心肌病发生中具有关键病理生理作用。
  • 控制肝脏和/或心肌炎症(如使用选择性CB2受体激动剂)可能延缓或预防严重肝病中心肌病的发生。

研究设计与样本

  • 研究采用胆管结扎(BDL)诱导肝纤维化小鼠模型,通过超声心动图和心内压力-容积关系监测详细血流动力学,并评估心肌结构改变。
  • 使用选择性CB2受体激动剂治疗小鼠,以探索肝脏炎症和纤维化对心脏功能的影响。

主要发现

  • BDL诱导肝脏大量炎症(白细胞浸润、炎症细胞因子和趋化因子增加)、氧化应激、微血管功能障碍和纤维化。
  • BDL小鼠出现舒张、收缩及大血管功能受损,并伴有心脏炎症(巨噬细胞炎症蛋白1、白介素-1、P-选择素、CD45阳性细胞增加)和氧化应激(丙二醛、3-硝基酪氨酸和NADPH氧化酶增加)。
  • BDL小鼠肝脏和心脏中均观察到CB2受体上调。
  • CB2受体激活显著改善肝脏炎症、受损微循环和纤维化。
  • CB2受体激活降低血清肿瘤坏死因子-α水平,并改善心脏功能障碍、心肌炎症和氧化应激。

临床怎么用

  • 在严重肝病中,控制肝脏和/或心肌炎症(例如使用选择性CB2受体激动剂)可能延缓或预防心肌病的发生。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatic cardiomyopathy, a special type of heart failure, develops in up to 50% of patients with cirrhosis and is a major determinant of survival. However, there is no reliable model of hepatic cardiomyopathy in mice. We aimed to characterize the detailed hemodynamics of mice with bile duct ligation (BDL)-induced liver fibrosis, by monitoring echocardiography and intracardiac pressure-volume relationships and myocardial structural alterations. Treatment of mice with a selective cannabinoid-2 receptor (CB2 -R) agonist, known to attenuate inflammation and fibrosis, was used to explore the impact of liver inflammation and fibrosis on cardiac function. APPROACH AND RESULTS: BDL induced massive inflammation (increased leukocyte infiltration, inflammatory cytokines, and chemokines), oxidative stress, microvascular dysfunction, and fibrosis in the liver. These pathological changes were accompanied by impaired diastolic, systolic, and macrovascular functions; cardiac inflammation (increased macrophage inflammatory protein 1, interleukin-1, P-selectin, cluster of differentiation 45-positive cells); and oxidative stress (increased malondialdehyde, 3-nitrotyrosine, and nicotinamide adenine dinucleotide phosphate oxidases). CB2 -R up-regulation was observed in both livers and hearts of mice exposed to BDL. CB2 -R activation markedly improved hepatic inflammation, impaired microcirculation, and fibrosis. CB2 -R activation also decreased serum tumor necrosis factor-alpha levels and improved cardiac dysfunction, myocardial inflammation, and oxidative stress, underlining the importance of inflammatory mediators in the pathology of hepatic cardiomyopathy. CONCLUSIONS: We propose BDL-induced cardiomyopathy in mice as a model for hepatic/cirrhotic cardiomyopathy. This cardiomyopathy, similar to cirrhotic cardiomyopathy in humans, is characterized by systemic hypotension and impaired macrovascular and microvascular function accompanied by both systolic and diastolic dysfunction. Our results indicate that the liver-heart inflammatory axis has a pivotal pathophysiological role in the development of hepatic cardiomyopathy. Thus, controlling liver and/or myocardial inflammation (e.g., with selective CB2 -R agonists) may delay or prevent the development of cardiomyopathy in severe liver disease.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Matyas C, Erdelyi K, Trojnar E, et al. Interplay of Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy. Hepatology. 2020. PMID: 31469200. doi:10.1002/hep.30916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。